Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial Academic Article Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Genetic Predisposition to Disease

abstract

  • AstraZeneca.

publication date

  • July 6, 2010

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(10)60892-6

PubMed ID

  • 20609467

Additional Document Info

start page

  • 235

end page

  • 44

volume

  • 376

number

  • 9737